Francis Cuss - Bristol Myers Executive Vice President Chief Scientific Officer
President
Dr. Francis M. Cuss is Executive Vice President, Chief Scientific Officer of BristolMyers Squibb Co. Dr. Cuss joined BristolMyers Squibb in 2003 as senior vice president, Drug Discovery, adding responsibility for Discovery Medicine and Clinical Pharmacology in May 2006. Under Dr. Cuss leadership, BristolMyers Squibb has consistently been rated a research organization based on cycle time, success rates and costs, having increased discovery output while maintaining a flat operating budget. Dr. Cuss and his team integrated Adnexus, Medarex and ZymoGenetics into the research organization, and have driven innovation in the research operating model, processes and governance. Dr. Cuss became a member of the company Senior Management Team in 2010. Prior to joining BristolMyers Squibb, Dr. Cuss spent 14 years at ScheringPlough and three years at Glaxo, holding positions of increasing responsibility in discovery, clinical research and medical affairs in both the U.S. and Europe. Prior to joining the pharmaceutical industry, Dr. Cuss was a practicing physician and held several academic appointments, including as adjunct associate professor at Jefferson Medical College at Thomas Jefferson University in Philadelphia. Dr. Cuss received his medical training in the U.K. and holds medical degrees from Cambridge University. He is also a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine. since 2013.
| Age | 60 |
| Tenure | 11 years |
| Phone | 212-546-4000 |
| Web | http://www.bms.com |
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Mark Fishman | Novartis AG ADR | 63 | |
| Mark Mallon | AstraZeneca PLC ADR | N/A | |
| Sean Bohen | AstraZeneca PLC ADR | N/A | |
| George Grofik | Sanofi ADR | N/A | |
| Luke Miels | AstraZeneca PLC ADR | N/A | |
| Hal Barron | GlaxoSmithKline PLC ADR | 58 | |
| Ruud Dobber | AstraZeneca PLC ADR | N/A | |
| Patrick Vallance | GlaxoSmithKline PLC ADR | 57 | |
| William Sibold | Sanofi ADR | 51 | |
| Alan Main | Sanofi ADR | 64 | |
| CA BSc | GlaxoSmithKline PLC ADR | 58 | |
| MarieFrance Tschudin | Novartis AG ADR | 53 | |
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
| Claire Thomas | GlaxoSmithKline PLC ADR | N/A | |
| DavidAlexandre Gros | Sanofi ADR | 42 | |
| Katarina Ageborg | AstraZeneca PLC ADR | N/A | |
| Luke Miels | AstraZeneca PLC | N/A | |
| Bahija Jallal | AstraZeneca PLC ADR | 55 | |
| Pam Cheng | AstraZeneca PLC ADR | 54 | |
| Ruud Dobber | AstraZeneca PLC | N/A | |
| Nate Crisel | Astellas Pharma | N/A | |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
| Togo West, Independent Director | ||
| Karen Vousden, Director | ||
| Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
| Alan Lacy, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Jose Baselga, Independent Director | ||
| Charles Bancroft, CFO, Executive Vice President | ||
| Gerald Storch, Independent Director | ||
| Louis Schmukler, President - Global Manufacturing and Supply | ||
| Michael Grobstein, Independent Director | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
| John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
| Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
| Karen Santiago, Senior Vice President Controller | ||
| Giovanni Caforio, COO, Director | ||
| Vicki Sato, Independent Director | ||
| Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
| Joseph Caldarella, Senior Vice President Corporate Controller | ||
| Laurie Glimcher, Independent Director | ||
| Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
| Lamberto Andreotti, CEO, Director | ||
| Thomas Lynch, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Lewis Campbell, Independent Director | ||
| Theodore Samuels, Independent Director | ||
| Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Senior Vice President - Global Human Resources | ||
| Sandra Leung, General Counsel, Corporate Secretary | ||
| Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
| Francis Cuss, Executive Vice President Chief Scientific Officer | ||
| Paul Biondi, Senior Vice President Head - Business Development | ||
| Peter Arduini, Independent Director |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Bristol Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol Myers' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |